ArticleJournal of thoracic disease2025
Single atom-substituted gold nanoclusters for alleviating neural injury induced by deep hypothermic circulatory arrest.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurological deficit is a common complication of deep hypothermic circulatory arrest (DHCA). Among the diverse factors contributing to neural injury, oxidative stress plays a prominent role. Emerging nanocluster technology has demonstrated considerable antioxidant and anti-inflammation activity. In this study, we developed a novel type of nanocluster for the treatment of neural injury induced by DHCA. Methods: Single atom-substituted gold nanoclusters (AuNCs) were synthesized. PC-12 cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) and a rat DHCA model were employed. Cell viability was evaluated via Cell Counting Kit-8 (CCK-8). Histopathological changes in the hippocampus were evaluated by hematoxylin-eosin staining. S100 calcium-binding protein β (S100β), neuron-specific enolase (NSE), malondialdehyde (MDA), and interleukin-1β (IL-1β) levels were determined by enzyme-linked immunosorbent assay (ELISA). Expression of S100β, caspase-3, and cleaved caspase-3 was assessed via Western blotting. Results: AuNCs exhibited strong antioxidant capacities, mimicking superoxide dismutase (SOD) and catalase (CAT) activities. Conclusions: The newly developed AuNCs alleviated the neural injury induced by DHCA through anti-inflammation, antioxidant, and anti-apoptosis activity. These findings offer a novel avenue for achieving perioperative brain protection in clinical DHCA and provide a new direction for developing catalysts in medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.